In summary, targeting different types of cancer through induction of ferroptosis is a promising therapeutic strategy, and several efforts are currently underway to develop selective GPX4, SLC7A11 and FSP1 inhibitors with enhanced bioavailability. The gene discussed is GPX4; the disease is cancer.